Drug Trial Radar · NCT06400485
AMT-676 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Jun 18, 2024
Primary completion
May 15, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Multitude Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- May 6, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, open-label, multicenter Phase Ia/Ib study of AMT- 676, followed by an open-label, multicenter, dose-escalation.
Conditions
- Advanced Solid Tumors
Interventions
AMT-676Drug
Participants will receive AMT-676 administered intravenously. Participants will be observed for first instance of dose limiting toxicities (DLT).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase 2 Dose (RP2D)Time frame: 30 days after the last dose of IMP
- Maximum Tolerated Dose (MTD)Time frame: 30 days after the last dose of IMP
- Type, incidence and severity of Adverse EventsTime frame: 30 days after the last dose of IMP
Locations
13 sites in 3 countries. Site status is shown where the registry gives one.
Carolina Biooncology Institute
Huntersville, North Carolina, American Samoa · Not yet recruiting
John Hopkins Sidney Kimmel Comprehensive Cancer Center
Philadelphia, Pennsylvania, American Samoa · Not yet recruiting
South Texas Accelerated Research Therapeutics (start) San Antonio
San Antonio, Texas, American Samoa · Not yet recruiting
SCIENTIA Clinical Research Ltd
Randwick, New South Wales, Australia · Recruiting
Macquarie University Hospital
Macquarie, New South wWales, Australia · Recruiting
Gallipoli Medical Research Foundation
Greenslopes, Queensland, Australia · Recruiting
Cabrini Hospital
Melbourne, Victoria, Australia · Recruiting
Linear Research
Nedlands, Western Australia, Australia · Recruiting
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Not yet recruiting
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China · Not yet recruiting
Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.